Key facts
- It has raised $1.0M across 2 recorded rounds; the latest was Early Stage VC ($5.0M) in Mar 2026.
- Notable investors include 1517 Fund, Later Capital, Unshackled Ventures.
- Reprogram Biosciences has filed 1 Form D with the SEC, most recently May 2025 ($1.0M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Reprogram Biosciences
Funding rounds
2 roundsAbout Reprogram Biosciences
Operator of an innovative biotechnology company intended to focus on cancer treatment. The company offers a groundbreaking immunotherapy approach that utilizes gene reprogramming to transform cancer cells into immune cell types by leveraging a novel therapeutic gene cocktail and a targeted delivery system, enabling users to make effective treatments simpler and faster for patients everywhere.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 3
- Website
- reprogrambio.com/
- Ownership
- Privately Held (backing)
Reprogram Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reprogram Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reprogram Biosciences in its N-PORT filings yet. We sweep new filings monthly.